ScholarIQanswers from OpenAlex
Xihua University
InstitutionResearch output, impact & collaborations
Xihua University is a institution indexed in ScholarIQ from OpenAlex.
What is known about Xihua University?
ScholarIQrecord summary
Xihua University is a research organisation in Chengdu, CN. OpenAlex records 17,649 works and 424,630 citations for it. 7,534 researchers list it as their most recent affiliation.
How many works does Xihua University have?
ScholarIQindexed works
Xihua University has 17,649 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Xihua University have?
ScholarIQcitation count
Xihua University has 424,630 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Xihua University?
ScholarIQresearcher count
Xihua University has 7,534 researchers in the ScholarIQ index.
What is the average h-index at Xihua University?
ScholarIQavg h-index
Xihua University has an average h-index of 76.3 in OpenAlex.
What is the ROR of Xihua University?
ScholarIQror
The ROR for Xihua University is on the source record.
What is the OpenAlex record for Xihua University?
ScholarIQopenalex
The OpenAlex for Xihua University is on the source record.
What is the Wikidata of Xihua University?
ScholarIQwikidata
The Wikidata for Xihua University is on the source record.
Who are the most-cited researchers behind Xihua University?
ScholarIQtop researchers by citations
What are the most-cited papers on Xihua University?
ScholarIQmost cited works
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw, Kari Chansky, John Crowley, Ramón Rami–Porta, Hisao Asamura, Wilfried Eberhardt, Andrew G. Nicholson, Patti A. Groome, Alan Mitchell, Vanessa Bolejack, Peter Goldstraw, Ramón Rami–Porta, Hisao Asamura, David Ball, David G. Beer, Ricardo Beyruti, Vanessa Bolejack, Kari Chansky, John Crowley, Frank Detterbeck, Wilfried Eberhardt, John Edwards, Françoise Galateau-Sallé, Dorothy J. Giroux, Fergus Gleeson, Patti A. Groome, James Huang, Catherine Kennedy, Jhingook Kim, Young Tae Kim, Laura Kingsbury, Haruhiko Kondo, Mark Krasnik, Kaoru Kubota, Antoon Lerut, Gustavo Lyons, Mirella Marino, Edith M. Marom, Jan P. van Meerbeeck, Alan Mitchell, Takashi Nakano, Andrew G. Nicholson, Anna K. Nowak, Michael Peake, Thomas W. Rice, Kenneth E. Rosenzweig, Enrico Ruffini, Valerie W. Rusch, Nagahiro Saijo, Paul Van Schil, Jean‐Paul Sculier, Lynn Shemanski, Kelly Stratton, Kenji Suzuki, Yuji Tachimori, Charles F. Thomas, William D. Travis, Ming‐Sound Tsao, Andrew T. Turrisi, Johan Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, Paul Baas, Jeremy Erasmus, Seiki Hasegawa, Kouki Inai, Kemp H. Kernstine, Hedy L. Kindler, Lee M. Krug, Kristiaan Nackaerts, Harvey I. Pass, David C. Rice, Conrad Falkson, Pier Luigi Filosso, Giuseppe Giaccone, Kazuya Kondo, Marco Lucchi, Meinoshin Okumura, Eugene H. Blackstone, F. Abad Cavaco, Emilio Ansótegui Barrera, J. Abal Arca, Isaura Parente Lamelas, A. Arnau Obrer, R. Guijarro Jorge, David Ball, G.K. Bascom, Ana Isabel Blanco Orozco, M.A. González Castro, Matthew G. Blum, Domingo Chimondeguy, Vlado Cvijanović, Sebastián Defranchi, B. de Olaiz Navarro, I. Escobar Campuzano, I. Macía Vidueira, E. Fernández Araujo, Felipe Andreo García, Kwun M. Fong, Gloria Francisco Corral
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares
How much of the research on Xihua University is open access?
ScholarIQopen access share
67%OPEN ACCESS